

Zachary C Hartman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/741467/publications.pdf>

Version: 2024-02-01

35
papers

1,841
citations

430874

18
h-index

477307

29
g-index

35
all docs

35
docs citations

35
times ranked

3512
citing authors

#	ARTICLE	IF	CITATIONS
1	Growth of Triple-Negative Breast Cancer Cells Relies upon Coordinate Autocrine Expression of the Proinflammatory Cytokines IL-6 and IL-8. <i>Cancer Research</i> , 2013, 73, 3470-3480.	0.9	342
2	Adenovirus vector induced innate immune responses: Impact upon efficacy and toxicity in gene therapy and vaccine applications. <i>Virus Research</i> , 2008, 132, 1-14.	2.2	204
3	Increasing vaccine potency through exosome antigen targeting. <i>Vaccine</i> , 2011, 29, 9361-9367.	3.8	166
4	T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes. <i>Cell</i> , 2019, 178, 1016-1028.e13.	28.9	150
5	Adenovirus Infection Triggers a Rapid, MyD88-Regulated Transcriptome Response Critical to Acute-Phase and Adaptive Immune Responses In Vivo. <i>Journal of Virology</i> , 2007, 81, 1796-1812.	3.4	135
6	HER2 Overexpression Elicits a Proinflammatory IL-6 Autocrine Signaling Loop That Is Critical for Tumorigenesis. <i>Cancer Research</i> , 2011, 71, 4380-4391.	0.9	116
7	Adenoviral infection induces a multi-faceted innate cellular immune response that is mediated by the toll-like receptor pathway in A549 cells. <i>Virology</i> , 2007, 358, 357-372.	2.4	77
8	CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis. <i>JCI Insight</i> , 2019, 4, .	5.0	77
9	Mechanisms of Therapeutic Antitumor Monoclonal Antibodies. <i>Cancer Research</i> , 2021, 81, 4641-4651.	0.9	67
10	Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors. <i>Oncolmmunology</i> , 2018, 7, e1421891.	4.6	57
11	Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study. <i>Clinical Cancer Research</i> , 2019, 25, 2725-2736.	7.0	50
12	Truncated ErbB2 Expressed in Tumor Cell Nuclei Contributes to Acquired Therapeutic Resistance to ErbB2 Kinase Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1367-1374.	4.1	45
13	Optical and Radioiodinated Tethered Hsp90 Inhibitors Reveal Selective Internalization of Ectopic Hsp90 in Malignant Breast Tumor Cells. <i>Chemistry and Biology</i> , 2013, 20, 1187-1197.	6.0	43
14	Ligand-Independent Toll-like Receptor Signals Generated by Ectopic Overexpression of MyD88 Generate Local and Systemic Antitumor Immunity. <i>Cancer Research</i> , 2010, 70, 7209-7220.	0.9	36
15	Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and \hat{I} \pm PD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4670-4681.	7.0	31
16	Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system. <i>Virology</i> , 2008, 374, 453-467.	2.4	30
17	Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio. , 2020, 8, e001662.		28
18	An Adenoviral Vaccine Encoding Full-Length Inactivated Human Her2 Exhibits Potent Immunogenicity and Enhanced Therapeutic Efficacy without Oncogenicity. <i>Clinical Cancer Research</i> , 2010, 16, 1466-1477.	7.0	24

#	ARTICLE	IF	CITATIONS
19	Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy. <i>Onc Immunology</i> , 2017, 6, e1264563.	4.6	23
20	Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition. <i>Onc Immunology</i> , 2017, 6, e1315495.	4.6	17
21	<i>In Vivo</i> Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior. <i>Clinical Cancer Research</i> , 2017, 23, 7531-7542.	7.0	15
22	Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. <i>Breast Cancer Research</i> , 2018, 20, 90.	5.0	14
23	IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils. <i>Cancer Research</i> , 2020, 80, 3088-3100.	0.9	14
24	Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis. <i>JCI Insight</i> , 2022, 7, .	5.0	14
25	An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1529-1544.	4.2	12
26	Progesterone promotes immunomodulation and tumor development in the murine mammary gland. , 2021, 9, e001710.		12
27	Right Time and Place for IL12: Targeted Delivery Stimulates Immune Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 9-11.	7.0	10
28	HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression. , 2020, 8, e000258.		9
29	Cancer vaccine strategies using self-replicating RNA viral platforms. <i>Cancer Gene Therapy</i> , 2023, 30, 794-802.	4.6	8
30	Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression. , 2022, 10, e003721.		6
31	HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase. <i>Molecular Cancer Research</i> , 2021, 19, 1699-1711.	3.4	5
32	Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitors. <i>Oncotarget</i> , 2021, 12, 1-3.	1.8	2
33	HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 217-226.	4.1	2
34	Abstract NG15: Progesterone-mediated immune evasion in breast cancer. , 2021, , .		0
35	How can we create precision immunotherapy as standard in breast cancer?. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1179-1181.	2.4	0